Aim: assess the epidemiology of Hepatitis-Associated Aplasia (HAA) and compare treatment outcome of HAA with non-HAA patients. Patients. We evaluated 3916 aplastic anemia patients reported to the European Registry between 1990 and 2007. Year, month ,season of diagnosis, type and outcome of first line therapy were analyzed .
are therefore classified as idiopathic. A small proportion of patients , however, will develop pancytopenia following an acute episode of hepatitis, and this is referred to as hepatitis -associated aplastic anaemia (HAA; . Indeed, clinically apparent hepatitis precedes Aplasia by a period of weeks to months, typically in young males. Although hepatitis usually, but not always, follows a benign and unremarkable course, the subsequent aplasia, if not treated, is often fatal .As to the frequency of HAA, it varies according to the geographic area: a prior episode of hepatitis is reported in 2-5% of aplastic patients in Europe and North America series, while its occurrence is up to 10% in Far East Countries (Baumelou E et al, 1993; Young NS et al, 1986) .
The presumed cause of hepatitis is still unknown, since the vaste majority of cases are seronegative for hepatotropic viruses like hepatitis A, B and C, GBV-C and other Flaviviridiae (Hibbs JR et al, 1992; Safadi R et al, 2001) . Clinical features and experimental results strongly suggest a central role for an immune-mediated pathogenesis. One of the possible mechanisms for HAA, as well as for idiopatic aplasia, is T-cell mediated suppression of bone marrow , and liver infiltration with activated CD8 cells (Lu J et al, 2004) . Treatment protocols include allogeneic bone marrow transplantation (BMT) and combined immunosuppressive therapy (IS) when a suitable donor is lacking. Due to the rarity of the disease, reports on treatment results are scarce, contradicting and based on small numbers: a very poor prognosis has been described in early studies (Ajlouni K et al, 1974 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 show that treatment results in HAA are comparable to those obtained in other forms of acquired aplastic anemia both with BMT and IS Witherspoon RP et al, 1984; Kiem HP et al, 1996; Locasciulli A et al, 1990; Osugi Y et al, 1978) . The aim of the present study was to analyse epidemiology and treatment results in a large European series of HAA reported to the Severe Aplastic Anemia Registry of the EBMT -SAA Working Party since 1990. To better ascertain prognosis in this particular form of marrow aplasia, we also compared treatment results to those obtained in Idiopatic Aplastic Anemia patients referred to the Registry during the same time-period. 
MATERIALS and METHODS

Design
Prevalence of HAA
A total of 3916 patients with acquired aplastic anemia, diagnosed according to current criteria ( Camitta BM et al, 1978) were treated in Europe , between 1990 and 2007 , and were reported to the SAA-WP Registry. Hepatitis -associated aplastic anemia (HAA) accounted for 214 cases (5.4%). Non-HAA patients: 1485 patients with non-HAA received Immunosuppression (IS) as first line therapy. The median interval between diagnosis and treatment is 27 days (range 0-3956) .
Neutrophil counts at the time of treatment were available in 1350 patients , and allowed for classification of AA as very severe (31%), severe (22%) and non severe (31%). Median follow-up at the time of analysis was 1911 days (range 0-6468) for patients surviving , and 382 days (range 1-5138) for deceased patients, respectively. IS therapy consisted on anti-thymocyte globulin (ATG) and Cyclosporin (CyA) in the majority of patients, regardless of etiology: 582 received ATG+CyA and 487 received ATG+CyA+ growth factor, 154 ATG alone. Most patients received the horse formulation as first line therapy; rabbit ATG was used more rarely as first line, but commonly as second line therapy.
Hepatitis associated aplastic anemia. A total of 75 patients with HAA received Immunosuppression as first line therapy: 31 received ATG+CyA , 24 received ATG+CyA+ growth factor and 9 ATG alone. Median interval between diagnosis and IS was 10 days (range 0-3788).
Bone Marrow Transplantation
Non-HAA patients. A total of 2217 patients with non hepatitis associated aplasia, received a BMT .
The median interval from diagnosis to treatment was 108 days (1-5477) . The majority of patients were grafted from an HLA identical sibling (74%) , and received marrow as a stem cell source (70%)
.
Hepatitis associated aplastic anemia. A total of 214 patients with HAA were allografted, most of them with marrow (82%) from an identical sibling (83%). Median interval between diagnosis and BMT was shorter than idiopathic AA (75 vs 108 days, p=0.0001) (range 12-2063).
Statistical analysis
The students T and Mann Whitney tests were used for continuous variables , the Chi-square for 2x2 tables and the log-rank test for time dependent variables and Kaplan Meier curves were used for actuarial survival. A COX multivariate analysis was run separately on patients receiving first line IS or first line BMT, with survival as an end point: variables entered in the model were patient age, interval diagnosis-treatment (cut off =median interval in days), etiology of AA (and year of treatment.
The number cruncher software (NCSS, version 5.0; JL Hintze, Kaysville, UT) was used to perform the analysis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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RESULTS
Prevalence of HAA . The average prevalence of HAA in Europe , between 1990 and 2007 , was 5.4%, and the median was 7% , with a range between 0% and 30%. Indeed, the distribution among Centers who registered aplastic anemia patients in this time period was not homogeneous, with prevalence peaks of HAA up to 15% (Table 1) . However, we must consider that the Registry includes both large Centers providing more than 400 cases each, and others with only scattered registered patients per year (Table 1) . There was no significant difference in distribution of both HAA and all the other acquired aplastic anemia according to month (p >0.1) and year of diagnosis (p = 0.6). There was no causative virus for hepatitis in 94% of HAA patients; in 15 cases it was a hepatits virus (6%): of these 9 were hepatitis B virus and 6 hepatitis A virus. The age at diagnosis was significantly younger in HAA patients: 15 (range 2-73) versus 20 years ( range 1-94) in other acquired AA (p<0.01) ( Table 2 ). There was also a male prevalence in HAA (68% vs 58% ,p=0.002) ( Table 2 ) .
Immunosuppression. The overall actuarial 10 year survival of all 1560 patients given 1 st line IS therapy , is 68%: 69% for 75 HAA patients and 59% for 1485 non-HAA patients (p=0.5) ( Figure 1) .
Predictors of survival for IS patients in multivariate analysis were patients age , with a RR of 1.68 for patients over 20 years, a the interval diagnosis treatment, with a borderline RR of 1.2 for patients treated beyond 26 days from diagnosis (p=0.04) (Table 3) . There was no effect of etiology (HAA vs non-HAA) and of year of IS treatment. Causes of death were similar in patients with HAA and idiopathic AA , and included no response (18% and 21% ) , relapse (1% each) , secondary malignancy in (1.3 vs 1.4% ) .
Of the original 1560 patients given 1 st line IS, the proportion of patients requiring a second line transplant was identical in non-HAA and HAA patients: 29/75 (39%) vs 585/1485 (39%) (p=0.8) , and survival comparable.
Bone Marrow Transplantation.
The actuarial 10 year survival of 2356 patients receiving 1 st line BMT was 70% (56% for alternative donor BMT vs 75% for HLA identical sibling BMT). The median age of allografted patients was significantly younger in HAA (14 years , range 3-60) as compared to idiopathic AA (19 years, range 1-62): thus comparisons were made after stratification for age (<=/>20 years). Figure 2a shows actuarial survival for HAA patients <=20 years of age , grafted from HLA identical siblings (88%) compared to idiopathic AA (82%) (p=0.3). Figure 2b shows the same comparison for patients >20 years of age: 69% vs 65% survival (p=0.8) . The survival in patients grafted from alternative donors was also similar in HAA and idiopathic AA (69% vs 64%; p=0.7).
In multivariate COX analysis , predictors of survival were younger age (RR 1.5 for patients older than 20 years) ( and year of transplant (RR 0.82 for patients grafted after 1998).
Peripheral blood (PB) transplants had overall inferior outcome as compared to bone marrow (BM) transplants (66% vs 72%, p=0.002); this was true also after correcting for patient age (RR for BM vs IS 0.84, p=0.001). The effect was seen both for idiopathic as well as HAA patients. 1 ) and year of diagnosis (p = 0.8).We therefore couldn't identify seasonal peaks or periods of outbreaks in this study. As to the clinical characteristics, HAA patients were younger (15 vs 20 years), and there was a higher prevalence of males (68% vs 58%) thus confirming previous observations . The presumed cause of hepatitis is still unknown, being the vaste majority of cases seronegative for hepatotropic viruses like hepatitis A, B and C, GBV-C and other Flaviridiae (Hibbs JR et al, 1992; Safadi R et al, 2001 Among 2356 transplants, results were also similar between HAA and non-HAA patients. Because HAA patients are younger, survival was studied in two separate cohorts, less and over 20 years of age: with this stratification survival was superimposable. This is confirmed in a multivariate COX analysis, with age being the strongest negative predictor, followed by a longer interval between diagnosis and transplant. This is in keeping with the recent analysis on the EBMT risk score in patients with aplastic anemia (Gratwohl A et al, 2009 ). An overall improvement in outcome for transplant patients, is shown in the COX analysis , with a relative risk of 0.82 for patients grafted beyond 1998: this is probably due to improved supportive care, including new anti-infectious agents.
This study also confirms the negative impact of peripheral blood (PB) as a stem cell source as compared to bone marrow (BM), and again this was true for HAA and idiopathic AA.
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